



## AuroMedics – Recall of levetiracetam, levofloxacin and linezolid injection products

- On April 5, 2018, [AuroMedics announced](#) a user-level recall of all remaining unexpired lots of [levetiracetam](#), [levofloxacin](#), and [linezolid](#) injection products due to leaking bags.
  - Finished product release testing for both sterility and endotoxin was acceptable for all product lots and there have been no confirmed bag integrity-related complaints for the recalled products.

Product Description	NDC #
Levetiracetam in 0.82% sodium chloride injection, 500 mg/100 mL (5 mg/mL)	55150-246-47
Levetiracetam in 0.75% sodium chloride injection, 1000 mg/100 mL (10 mg/mL)	55150-247-47
Levetiracetam in 0.54% sodium chloride injection, 1500 mg/100 mL (15 mg/mL)	55150-248-47
Levofloxacin in 5% dextrose injection, 250 mg/50 mL	55150-243-46
Levofloxacin in 5% dextrose injection, 500 mg/100 mL	55150-244-47
Levofloxacin in 5% dextrose injection, 750 mg/150 mL	55150-245-52
Linezolid 600 mg/300 mL (2 mg/mL) injection	55150-242-51

- Levetiracetam is indicated as adjunctive therapy for adults (16 years and older) when oral administration is not feasible for the following: partial onset seizures; myoclonic seizures in patients with juvenile myoclonic epilepsy; and primary generalized tonic-clonic seizures.
- Levofloxacin is indicated for the treatment of adults with mild, moderate, and severe infections caused by susceptible isolates of certain microorganisms in nosocomial and community-acquired pneumonia; complicated and uncomplicated skin and skin structure infections; chronic bacterial prostatitis; inhalational anthrax; plague; complicated and uncomplicated urinary tract infections; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis; and acute bacterial sinusitis.
- Linezolid is indicated for the treatment of infections caused by susceptible strains of certain microorganisms in pneumonia, skin and skin structure infections, and vancomycin-resistant *Enterococcus faecium* infections.
- To date, AuroMedics has not received any reports of adverse events related to these products but is issuing this recall out of an abundance of caution.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using any of the recalled products.

- Anyone with recalled product should immediately quarantine and discontinue distribution of the recalled product. Contact AuroMedics Customer Service at **1-888-238-7880** for more information regarding this recall.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.